# US 2025/0144022 A1 · PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TNFAlpha ANTIBODY

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144022 A1
- Document ID: US20250144022A1
- Status: Published application
- Kind: A1
- Application number: 18/691,121
- Filed: 2022-09-15
- Published: 2025-05-08
- Earliest claimed: 2021-09-16
- Assignees: Aprogen, Inc.
- Applicants: APROGEN Inc.
- Inventors: Mijeong PARK; Seok Min JIN
- Web page: https://patentgrep.com/patent/US20250144022A1

## CPC

- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided is a stable pharmaceutical composition containing an anti-TNFα antibody. The pharmaceutical composition is characterized by being stable while containing a high concentration of the anti-TNFα antibody.

## Claims

### Claim 1

A pharmaceutical composition, comprising:
80 mg/ml to 200 mg/ml of an anti-TNFα antibody;
a buffer;
an excipient; and
a surfactant, and
having a pH of 4 to 7.5,
wherein,
the buffer comprises at least one selected from the group consisting of succinate, phosphate, acetate, and pharmaceutically acceptable salts thereof,
the excipient comprises at least one selected from the group consisting of mannitol, glycerol, glycine, and pharmaceutically acceptable salts thereof, and
the surfactant comprises polysorbate 20.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the buffer comprises at least one selected from the group consisting of succinate, phosphate, and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the buffer comprises succinate at a concentration of 10 mM or 20 mM, based on the total amount of the composition.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the excipient comprises mannitol, a combination of mannitol and glycerol, or a combination of mannitol and glycine.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the excipient comprises:
8.25 mM to 14 mM of mannitol and 239 mM to 293 mM of glycine; or
8.25 mM to 14 mM of mannitol and 217 mM to 272 mM of glycerol,
based on the total amount of the composition.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the surfactant comprises polysorbate 20 at a concentration of 0.01 to 0.1% (w/v), based on the total amount of the composition.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein, wherein the anti-TNFα antibody is adalimumab.

### Claim 8

A method for producing a stable liquid formulation of an anti-TNFα antibody, the method comprises a step of mixing
80 mg/ml to 200 mg/ml of the anti-TNFα antibody;
a buffer;
an excipient; and
a surfactant to prepare an aqueous liquid composition,
wherein,
the buffer comprises at least one selected from the group consisting of succinate, phosphate, acetate, and pharmaceutically acceptable salts thereof,
the excipient comprises at least one selected from the group consisting of mannitol, glycerol, glycine, and pharmaceutically acceptable salts thereof,
the surfactant comprises polysorbate 20, and
the aqueous liquid composition has a pH of 4 to 7.5.

### Claim 9 (depends on 8)

The method of claim 8, wherein the buffer comprises at least one selected from the group consisting of succinate, phosphate, and pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the buffer comprises succinate at a concentration of 10 mM or 20 mM, based on the total amount of the composition.

### Claim 11 (depends on 8)

The method of claim 8, wherein the excipient comprises mannitol, a combination of mannitol and glycerol, or a combination of mannitol and glycine.

### Claim 12 (depends on 11)

The method of claim 11, wherein the excipient comprises:
8.25 mM to 14 mM of mannitol and 239 mM to 293 mM of glycine; or
8.25 mM to 14 mM of mannitol and 217 mM to 272 mM of glycerol, based on the total amount of the composition.

### Claim 13 (depends on 8)

The method of claim 8, wherein the surfactant comprises polysorbate 20 at a concentration of 0.01 to 0.1% (w/v), based on the total amount of the composition.

### Claim 14 (depends on 8)

The method of claim 8, wherein the anti-TNFα antibody is adalimumab.

### Claim 15

A method for enhancing stability of an anti-TNFα antibody in a liquid formulation, the method comprising a step of mixing:
80 mg/ml to 200 mg/ml of the anti-TNFα antibody;
a buffer;
an excipient; and
a surfactant to prepare an aqueous liquid composition,
wherein,
the buffer comprises at least one selected from the group consisting of succinate, phosphate, acetate, and pharmaceutically acceptable salts thereof,
the excipient comprises at least one selected from the group consisting of mannitol, glycerol, glycine, and pharmaceutically acceptable salts thereof,
the surfactant comprises polysorbate 20, and
the aqueous liquid composition has a pH of 4 to 7.5.
